Figure 1

a-Study design for the evaluation of peanut protein passage into blood stream after epicutaneous application on intact or stripped skin. Naive mice were divided into 3 groups (n=10 for each). One group received a Viaskin® loaded with 500μg (Viaskin®-500) applied on intact skin (EPIT), another group received Viaskin®-500 applied on stripped skin (stripping+EPIT) and the last one received a subcutaneous injection containing 500μg of PPE. Blood samples were taken at different time points (0, 2, 8, 24, 48h) to quantify Ara h 1 in serum. b- Study design for the sensitization of mice to peanuts proteins and evaluation of the effect by EPIT on intact or stripped skin on the induction of digestive lesions on esophagus and jejunum. Twenty-four mice were sensitized to peanut proteins. Then, epicutaneous immunotherapy was conducted for 8 weeks in 8 sensitized mice on intact skin (EPIT), or in 8 sensitized mice on stripped skin (stripping+EPIT) and 8 other sensitized mice received a Sham treatment (Sham). After an oral challenge with high amounts of peanut proteins, histamine release was measured in blood samples. After that, a peanut regimen for 10 days was given to sensitized and naive mice. Mice were sacrificed to analyze esophagus and jejunum samples by histology and RT-qPCR. Blood samples were taken before the beginning of immunotherapy and after the 8-week period of treatment to measure specific immunoglobulins (IgE, IgG1, IgG2a).